89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors

被引：0
|
作者：
Giesen, D. [1 ]
Broer, L. N. [1 ]
Lub-De Hooge, M. N. [2 ]
Popova, I. [3 ]
Howng, B. [3 ]
Vasiljeva, O. [3 ]
de Vries, E. G. E. [1 ]
Pool, M. [4 ]
机构：
[1] Univ Med Ctr Groningen, Med Oncol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, Groningen, Netherlands
[3] CytomX Therapeut Inc, San Francisco, CA USA
[4] Leiden Univ, Med Ctr, Clin Pharm & Toxicol, Leiden, Netherlands
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] 89Zr-labeled anti-PD-L1 Probody therapeutic CX-072 biodistribution in mice bearing human xenograft or murine syngeneic tumors
    Giesen, Danique
    Broer, Linda N.
    Lub-de Hooge, Marjolijn N.
    Popova, Irina
    Howng, Bruce
    Vasiljeva, Olga
    de Vries, Elisabeth G.
    Pool, Martin
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072
    Stroh, Mark
    Green, Michelle
    Millard, Bjorn L.
    Apgar, Joshua F.
    Burke, John M.
    Garner, Will
    Lu, Hong
    Lyman, Susan K.
    Desnoyers, Luc R.
    Richardson, Jennifer
    Hannah, Alison
    Kavanaugh, W. Michael
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 383 - 393
  • [3] Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
    Li, Dan
    Cheng, Siyuan
    Zou, Sijuan
    Zhu, Dongling
    Zhu, Tinghui
    Wang, Pilin
    Zhu, Xiaohua
    MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1674 - 1681
  • [4] Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
    Bouleau, Alizee
    Nozach, Herve
    Dubois, Steven
    Kereselidze, Dimitri
    Chevaleyre, Celine
    Wang, Cheng-, I
    Evans, Michael J.
    Lebon, Vincent
    Maillere, Bernard
    Truillet, Charles
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1259 - 1265
  • [5] 89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Moon, Seung Hwan
    Cho, Young Seok
    Lee, Kyung-Han
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (05) : 656 - 664
  • [6] Imaging of PD-L1 modulation by gemcitabine using 89Zr labeled anti-PD-L1 antibody PET.
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Cho, Young Seok
    Lee, Kyung-Han
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 90 - 91
  • [7] 89Zr-Labeled Anti-PD-L1 Antibody Fragment for EvaluatingIn VivoPD-L1 Levels in Melanoma Mouse Model
    Bridgwater, Caleb
    Geller, Anne
    Hu, Xiaoling
    Burlison, Joe A.
    Zhang, Huang-Ge
    Yan, Jun
    Guo, Haixun
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (08) : 549 - 557
  • [8] Dose-dependent targeting of 89Zr-labeled atezolizumab (anti-PD-L1 antibody) to PD-L1 expressing tumor xenografts
    Longtine, Mark
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [9] First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody
    de Ruijter, Laura Kist
    Hooiveld-Noeken, Jahlisa S.
    Giesen, Danique
    Lub-de Hooge, Marjolijn N.
    Kok, Iris C.
    Brouwers, Adrienne H.
    Elias, Sjoerd G.
    Nguyen, Margaret T. L.
    Lu, Hong
    Gietema, Jourik A.
    Jalving, Mathilde
    de Groot, Derk J. A.
    Vasiljeva, Olga
    de Vries, Elisabeth G. E.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5325 - 5333
  • [10] PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas
    Spira, Alexander I.
    Middleton, Mark R.
    Naing, Aung
    Autio, Karen A.
    Nemunaitis, John J.
    Bendel, Johanna C.
    Gordon, Michael
    Humphrey, Rachel W.
    Wong, Chihunt
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345